Chris Cardon, Ziphius Vaccines CEO
May 25, 2021 10:26 AM EDT
Financing
Coronavirus

Spurred on by Mod­er­na and Pfiz­er's suc­cess, a Bel­gian biotech has big am­bi­tions for its self-am­pli­fy­ing RNA vac­cine play

Josh Sullivan

With the first wave of mR­NA-based Covid-19 vac­cines pro­vid­ing proof of con­cept to the en­tire field, in­vestors are see­ing dol­lar signs for plat­form plays once …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times